Chihiro Yamamoto, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Shuka Furuki, Atsuto Noguchi, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Shin-Ichiro Kawaguchi, et al. Impact of Real-World Clinical Factors on an Analysis of the Cost-Effectiveness of "Immediate CAR-T" Versus "Late CAR-T" as Second-Line Treatment for DLBCL Patients. Transplant Cell Ther. 2025. 31. 5
Hirotomo Nakashima, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Takashi Ikeda, et al. Risk factors for influenza virus infection in patients with hematological disease. Leukemia & lymphoma. 2025. 1-7
Yumiko Toda, Masahiro Ashizawa, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, et al. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era. International journal of hematology. 2024. 119. 6. 660-666
Iekuni Oh, Kaoru Hatano, Takashi Ikeda, Yumiko Toda, Daisuke Minakata, Shinichiro Kawaguchi, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, et al. Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults. Leukemia research. 2024. 137. 107438-107438
Chihiro Yamamoto, Daisuke Minakata, Daizo Yokoyama, Shuka Furuki, Atsuto Noguchi, Shunsuke Koyama, Takashi Oyama, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, et al. Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed/ refractory multiple myeloma. Transplantation and cellular therapy. 2023